IN2014DN07799A - - Google Patents
Info
- Publication number
- IN2014DN07799A IN2014DN07799A IN7799DEN2014A IN2014DN07799A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A IN 7799DEN2014 A IN7799DEN2014 A IN 7799DEN2014A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A
- Authority
- IN
- India
- Prior art keywords
- antibody
- present disclosure
- rob04
- angiogenesis
- pharmaceutical composition
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 4
- 230000003527 anti-angiogenesis Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (ja) | 2012-04-27 | 2012-04-27 | 抗ｒｏｂｏ４抗体 |
| JP2013011042A JP2014141434A (ja) | 2013-01-24 | 2013-01-24 | 抗ｒｏｂｏ４抗体 |
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07799A true IN2014DN07799A (zh) | 2015-05-15 |
Family
ID=48670623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7799DEN2014 IN2014DN07799A (zh) | 2012-04-27 | 2013-04-26 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9683040B2 (zh) |
| EP (1) | EP2841457B1 (zh) |
| JP (2) | JP5897205B2 (zh) |
| KR (2) | KR20190020838A (zh) |
| CN (1) | CN104768973B (zh) |
| AU (1) | AU2013254313B2 (zh) |
| BR (1) | BR112014026649A2 (zh) |
| CA (1) | CA2868074A1 (zh) |
| CO (1) | CO7111295A2 (zh) |
| DK (1) | DK2841457T3 (zh) |
| ES (1) | ES2733434T3 (zh) |
| HK (1) | HK1207093A1 (zh) |
| IN (1) | IN2014DN07799A (zh) |
| MX (1) | MX356749B (zh) |
| MY (1) | MY166821A (zh) |
| NZ (1) | NZ629291A (zh) |
| PH (1) | PH12014502382B1 (zh) |
| PL (1) | PL2841457T3 (zh) |
| RU (1) | RU2682451C2 (zh) |
| SG (1) | SG11201405718QA (zh) |
| TW (1) | TWI606065B (zh) |
| WO (1) | WO2013160879A1 (zh) |
| ZA (1) | ZA201406235B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013160879A1 (en) * | 2012-04-27 | 2013-10-31 | Daiichi Sankyo Company, Limited | Anti-robo4-antibody |
| RU2769379C2 (ru) | 2015-09-24 | 2022-03-30 | Дайити Санкио Компани, Лимитед | Антитело против garp |
| EP3527225A4 (en) * | 2016-10-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT |
| KR20210070643A (ko) | 2019-12-05 | 2021-06-15 | 김명배 | 자체 발전 웨어러블 다리 |
| WO2023156437A1 (en) | 2022-02-16 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| EA013224B1 (ru) | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Клетки, продуцирующие композиции антител |
| PT1790728E (pt) | 2000-11-06 | 2010-11-12 | Cancer Rec Tech Ltd | Imagiologia, diagnóstico e tratamento de doença |
| JP4583638B2 (ja) * | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | アセチルリジン認識モノクローナル抗体及びその製造方法 |
| AU2003247828B2 (en) | 2002-06-27 | 2010-05-20 | University Of Utah Research Foundation | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| AU2003285500B8 (en) | 2002-11-20 | 2011-02-03 | Cancer Research Technology Limited | Antibodies binding to human magic roundabout (MR), polypeptides and uses thereof for inhibition of angiogenesis |
| KR101024443B1 (ko) | 2003-01-07 | 2011-03-23 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질의 제조 방법 |
| EP2104509A4 (en) | 2006-12-11 | 2010-03-24 | Univ Utah Res Found | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASCULAR PERMEABILITY |
| NZ578701A (en) * | 2007-02-09 | 2012-02-24 | Genentech Inc | Anti-robo4 antibodies and uses therefor |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| WO2013160879A1 (en) * | 2012-04-27 | 2013-10-31 | Daiichi Sankyo Company, Limited | Anti-robo4-antibody |
-
2013
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en active Application Filing
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/da active
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 MX MX2014012351A patent/MX356749B/es active IP Right Grant
- 2013-04-26 ES ES13730645T patent/ES2733434T3/es active Active
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/ja active Active
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/pt not_active Application Discontinuation
- 2013-04-26 PL PL13730645T patent/PL2841457T3/pl unknown
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/ko not_active Application Discontinuation
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/ko active IP Right Grant
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 US US14/397,210 patent/US9683040B2/en active Active
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/ru not_active IP Right Cessation
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/zh not_active Expired - Fee Related
- 2013-04-26 TW TW102115219A patent/TWI606065B/zh not_active IP Right Cessation
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382B1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/es unknown
-
2015
- 2015-08-10 HK HK15107712.5A patent/HK1207093A1/zh not_active IP Right Cessation
- 2015-12-11 US US14/966,292 patent/US9562096B2/en active Active
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07799A (zh) | ||
| PH12014501914A1 (en) | Anti sez6 antibodies and methods of use | |
| HK1215259A1 (zh) | 檢測抗苗勒管激素的同種型的抗體組合物及免疫測定方法 | |
| AU341611S (en) | Dual function wine system | |
| FI20116074A (fi) | Nestemäinen entsyymivalmiste ja menetelmä sen valmistamiseksi | |
| WO2014209905A3 (en) | Methods and compositions for detecting and diagnosing diseases and conditions | |
| IN2014MN02114A (zh) | ||
| EP2795574A4 (en) | METHOD FOR MEASURING THE ABSORPTION OF LIQUID IN AN ABSORBENT PRODUCT | |
| MX2015010429A (es) | Cetuximab con glicosilación modificada y sus usos. | |
| MX2014004211A (es) | Composiciones de recubrimiento para moldes y machos de fundicion inorganicos que comprenden esteres de acido formico y uso de los mismos. | |
| EP2925267A4 (en) | UNIFORM LIQUID INTAKE SYSTEM FOR ABSORBENT PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF | |
| SG11201400405TA (en) | Caninised antibodies and method for the production of same | |
| AU343147S (en) | Easel | |
| EP2912018A4 (en) | PROCESS AND CATALYST FOR THE PREPARATION OF PYRIDINE AND ALKYL DERIVATIVES THEREOF | |
| EP2831262A4 (en) | SECRETION OF FUNCTIONAL INSULING LARGINE DIRECTLY INTO THE CULTURE MEDIUM BY INTRA-CELLULAR OVEREXPRESSION OF KEX2P | |
| HK1223444A1 (zh) | 隨著時間推移從經綜合處理和分析後的數據信號推導出重大變化屬性以預測常規預測因子的未來變化的系統及方法 | |
| MX2016005645A (es) | Composicion farmaceutica topica de acitretina. | |
| FI20126231A (fi) | Kelluva saarirakenne ja menetelmä kelluvan saarirakenteen keinumisen estämiseksi | |
| BR112013032496A2 (pt) | método de fermentação de abe compreendendo absorção do produto através de isoforona | |
| IN2014MN01871A (zh) | ||
| HK1217231A1 (zh) | 小鼠血清中大鼠抗體的特異性檢測 | |
| EP3088079A4 (en) | Catalyst for use in production of methyl methacrylate, and method for producing methyl methacrylate | |
| EP2735547B8 (fr) | Nouveau procédé de production d'eau allégée en calcaire et dispositif de mise en oeuvre | |
| EP3064572A4 (en) | Method for producing induced pluripotent stem cell from mesenchymal stem cell and induced pluripotent stem cell produced by the method | |
| UA65610U (ru) | Способ диагностики эндогенных и экзогенных психических расстройств |